All In Biotech

Drug Trial Radar · NCT05721235

A Safety/Tolerability and PK Study With Azstarys® in Children With ADHD

A Multicenter, Dose-Optimized, Open-Label, Safety/Tolerability and Pharmacokinetic Study With Azstarys® in Children 4 and 5 Years of Age With Attention-Deficit/Hyperactivity Disorder

Last checked: Nov 20, 2026Latest source record: May 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

123

Actual

Start

Jun 2, 2023

Primary completion

Jul 31, 2025

Study completion Jul 31, 2025

Sponsor

Lead sponsor
Corium, Inc.Industry
Sponsor type
Industry
Collaborators
Premier Research; Prometrika, LLC; Almac; Worldwide Clinical Trials
First posted
Feb 9, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 4 years, up to 5 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The is a multicenter, dose-optimized, open-label, safety/ tolerability and pharmacokinetic (PK) study with Azstarys® in children 4 and 5 years of age with attention-deficit/hyperactivity disorder (ADHD). The primary objective is to determine the safety and tolerability of treating children 4 and 5 years-of-age with ADHD with Azstarys® for up 12 months. Approximately 100 subjects will be enrolled. Approximately 20 sites will participate.

Conditions

  • Attention Deficit/Hyperactivity Disorder

Interventions

  • Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)Drug

    Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changes in Sleep BehaviorTime frame: 12 Months
  2. Percent Change in Body WeightTime frame: 12 months
  3. Percentile Change in Body HeightTime frame: 12 Months
  4. Percentile Change in Body WeightTime frame: 12 months
  5. Percent Change in Body HeightTime frame: 12 Months

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • Preferred Research Partners (PRP)

    Little Rock, Arkansas

  • Advanced Research Center (ARC)

    Anaheim, California

  • IMMUNOe International Research Center

    Centennial, Colorado

  • Clinical Neuroscience Solutions - Orlando

    Jacksonville, Florida

  • Accel Research Sites - Lakeland

    Lakeland, Florida

  • Accel Research Sites - Maitland

    Maitland, Florida

  • South Florida Research Phase I-IV INC

    Miami Springs, Florida

  • CNS Healthcare - Orlando

    Orlando, Florida

  • iResearch Atlanta

    Decatur, Georgia

  • CenExel iResearch, LLC

    Savannah, Georgia

  • Sky Clinical Research Network Group P.C.

    Union City, Georgia

  • DelRicht Research - Touro Medical Center

    New Orleans, Louisiana

  • St Charles Psychiatric Associates & Midwest Research Group

    Saint Charles, Missouri

  • Boeson Research

    Missoula, Montana

  • Alivation Research, LLC

    Lincoln, Nebraska

  • Center For Psychiatry and Behavioral Medicine Inc

    Las Vegas, Nevada

  • Clinical Neuroscience Solution, Inc

    Memphis, Tennessee

  • Houston Clinical Trials

    Bellaire, Texas

  • AIM Trials

    Plano, Texas

  • Flourish Research

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.